Vascular Endothelial Growth Factor Is Expressed in Human Fetal Growth Cartilage

2010 ◽  
Vol 15 (3) ◽  
pp. 534-540 ◽  
Author(s):  
Marta Garcia-Ramirez ◽  
Nuria Toran ◽  
Pilar Andaluz ◽  
Antonio Carrascosa ◽  
Laura Audi
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Fetal Growth ◽  
Vascular Endothelial ◽  
Growth Cartilage ◽  
Endothelial Growth Factor

scholarly journals The diagnostic Value of Vascular Endothelial Growth Factor in Women with Growth-Restricted Fetuses

Doctor Ru ◽  
2020 ◽  
Vol 19 (8) ◽  
pp. 44-48
Author(s):  
I.F. Fatkullin ◽  
◽  
N.R. Akhmadeev ◽  
E.V. Ulyanina ◽  
L.Kh. Islamova ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Pregnant Women ◽  
Fetal Growth ◽  
Serum Levels ◽  
Diagnostic Value ◽  
Vascular Endothelial ◽  
Group I ◽  
Low Weight ◽  
Endothelial Growth Factor

Study Objective: To assess delivery outcomes in women with slow fetal growth (ICD-10 code P05) and study serum levels of vascular endothelial growth factor (VEGF) and its diagnostic value in patients with growth-restricted fetuses that have constitutional low weight, in order to choose an approach to pregnancy management. Study Design: This was a prospective and retrospective comparative study. Materials and Methods: The medical charts of 782 women who had given birth to low-weight babies in 2013 and 2014 were reviewed retrospectively. The prospective part of the study involved measuring serum levels of VEGF in 150 pregnant women: 50 women with growthrestricted fetuses (Group I), 50 women with low-weight fetuses without hemodynamic disruptions or placental abnormalities (Group II), and 50 women with healthy pregnancies (Group III). Based on the babies’ gestational term at birth, the women in each group were divided into two subgroups: between 22 weeks and 0 days and 31 weeks and 6 days (subgroup 1) and ≥32 weeks and 0 days (subgroup 2). The data obtained were processed using descriptive statistics and compared with data obtained through other fetal assessments. Study Results: The pregnant women with growth-restricted fetuses had higher VEGF levels by a statistically significant margin (p<0.00001) than the women in groups II and III: median levels were 310 (Q1–Q3: 270–508), 33 (Q1–Q3: 31–38), and 36 (Q1–Q3: 32–40) pg/mL, respectively, in subgroups 1 and 174 (Q1–Q3: 100–214), 78 (Q1–Q3: 73–86), and 82 (Q1–Q3: 78–88) pg/mL, respectively, in subgroups 2. VEGF levels ≥100 pg/mL were associated with fetal growth restriction (FGR) (p = 0.0001) and levels ≥200 pg/mL with a high risk of antenatal fetal death (p = 0.026) or early neonatal death (p = 0.03). Conclusion: For women with growth-restricted fetuses, VEGF serum levels ≥200 pg/mL are an additional risk factor for unfavorable perinatal outcomes, which helps to optimize obstetrical management for these patients. Keywords: low-weight fetus, fetal growth retardation, vascular endothelial growth factor.

scholarly journals Vascular Endothelial Growth Factor‐121 Administration Mitigates Halogen Inhalation‐Induced Pulmonary Injury and Fetal Growth Restriction in Pregnant Mice

2020 ◽  
Vol 9 (3) ◽  
Author(s):  
Dylan R. Addis ◽  
James A. Lambert ◽  
Changchun Ren ◽  
Stephen Doran ◽  
Saurabh Aggarwal ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Bronchoalveolar Lavage ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Vascular Endothelial ◽  
Pregnant Mice ◽  
Endothelial Growth Factor

Background Circulating levels of sFLT‐1 (soluble fms‐like tyrosine kinase 1), the extracellular domain of vascular endothelial growth factor (VEGF) receptor 1, and its ratio to levels of placental growth factor are markers of the occurrence and severity of preeclampsia. Methods and Results C57BL/6 pregnant mice on embryonic day 14.5 (E14.5), male, and non‐pregnant female mice were exposed to air or to Br 2 at 600 ppm for 30 minutes and were treated with vehicle or with VEGF‐121 (100 μg/kg, subcutaneously) daily, starting 48 hours post‐exposure. Plasma, bronchoalveolar lavage fluid, lungs, fetuses, and placentas were collected 120 hours post‐exposure. In Br 2 ‐exposed pregnant mice, there was a time‐dependent and significant increase in plasma levels of sFLT‐1 which correlated with increases in mouse lung wet/dry weights and bronchoalveolar lavage fluid protein content. Supplementation of exogenous VEGF‐121 improved survival and weight gain, reduced lung wet/dry weights, decreased bronchoalveolar lavage fluid protein levels, enhanced placental development, and improved fetal growth in pregnant mice exposed to Br 2 . Exogenous VEGF‐121 administration had no effect in non‐pregnant mice. Conclusions These results implicate inhibition of VEGF signaling driven by sFLT‐1 overexpression as a mechanism of pregnancy‐specific injury leading to lung edema, maternal mortality, and fetal growth restriction after bromine gas exposure.

scholarly journals Vascular endothelial growth factor role in predicting vascular disorders in pregnant with fetal growth restriction syndrome

2015 ◽  
Vol 96 (2) ◽  
pp. 220-223 ◽  
Author(s):  
E V Ul’yanina ◽  
I F Fatkullin
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factors ◽  
Growth Factor ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Blood Circulation ◽  
Growth Restriction ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

The review covers the up-to-date data of vascular endothelial growth factor role in forming of placental blood circulation in non-complicated pregnancy and in fetal growth retardation syndrome. It is shown that the normal trophoblast invasion to the spiral arteries wall in the myometrium and adequate remodeling of spiral arteries are essential for the normal fetal growth and development. The processes of blood vessels formation - vasculogenesis and angiogenesis - are described in detail. The process of angiogenesis regulation by growth factors and their receptors is reviewed. The importance of angiogenic and antiangiogenic factors coordinated action for the adequate placental microvasculature formation and normal fetal development is described. The growth factor complexes and their receptors formation processes and competition for receptor binding, as well as the role of placental growth factor in uteroplacental complex angiogenesis are analyzed. It is shown that the serum growth factors represent the mechanisms of pathologic reactions in placental insufficiency and fetal growth restriction syndrome. Special attention is given to the family of vascular endothelial growth factor as for the most important angiogenesis regulator. To determine the physiological role of vascular endothelial growth factor and to assess the its influence on angiogenesis and adequate uteroplacental and fetoplacental blood circulation formation, the features of vascular endothelial growth factor chemical structure are described. Determining the vascular endothelial growth factor in blood may be used to assess the mother-placenta-fetus system formation. The need for developing the criteria for choosing the optimal delivery term in pregnant with fetal growth restriction syndrome is discussed.

Sign in / Sign up

Export Citation Format

Share Document